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Abstract
Post-translational protein modifications are critical regulators of protein
functions as they expand the signaling potentials of the modified proteins, leading
to diverse physiological consequences. Currently, increasing evidence suggests
that protein methylation is as important as other post-translational modifications in
the regulation of various biological processes. This drives us to ask whether
methylation is involved in the EGFR (epidermal growth factor receptor) signaling,
a biological process extensively regulated by multiple post-translational
modifications including phosphorylation, glycosylation and ubiquitination. We
found that EGFR R1175 is methylated by a protein arginine methyltransferase
named PRMT5. During EGFR activation, PRMT5-mediated R1175 methylation
iv

specifically enhances EGF-induced EGFR autophosphorylation at Y1173 residue.
This novel modification crosstalk increases SHP1 recruitment to EGFR and
suppresses EGFR-mediated ERK activation, resulting in inhibition of cell
proliferation, migration, and invasion of EGFR-expressing cells. Based on these
findings, we provide the first link between arginine methylation and tyrosine
phosphorylation and identify R1175 methylation as an inhibitory modification
specifically against EGFR-mediated ERK activation.
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CHAPTER 1

INTRODUCTION

1.1 EGFR signaling and its biological effects
The epidermal growth factor receptor (EGFR) is a transmembrane
cell-surface receptor of the ErbB (erythroblastic leukemia viral oncogene homolog)
receptor tyrosine kinase family consisting of ErbB1 (EGFR), ErbB2 (Her2), ErbB3
and ErbB4. It is composed of an extracellular domain that provides ligand-binding
sites, a single transmembrane domain and a cytosolic region that contains a
juxtamembrane domain, a tyrosine kinase domain and a C-terminal tail segment[1,
2] (Figure 1). As a cell surface receptor, EGFR is able to convert extracellular
cues into intracellular effectors, leading to specified cellular responses. A general
accepted theory of EGFR activation is that binding of ligands, including EGF
(epidermal growth factor), TGF-(transforming growth factor-), HB-EGF
(heparin-binding EGF-like growth factor), AREG (amphiregulin), BTC
(betacellulin), EPG (epigen) and EPR (epiregulin) to the EGFR extracellular
domains causes structural change of the domains, exposure of dimerization arms
and induces dimerization of two receptor monomers[2-6]. EGFR can form either
homo-dimers or hetero-dimers with other family members[2, 7, 8]. Receptor
1

dimerization leads to activation of intrinsic tyrosine kinase domains[9] and
subsequent autophosphorylations on multiple tyrosine (Y) residues of the
C-terminal tail segments, including Y992, Y1045, Y1068, Y1086, Y1148 and
Y1173[10] (Figure 1). These tyrosine phosphorylations create docking motifs for
different cytosolic signaling molecules containing SH2 (Src homology 2) and PTB
(phosphotyrosine binding) domains[11]. Through recruiting these molecules,
EGFR initiates several downstream signaling cascades including the RAS
-RAF-MEK-ERK pathway (Ras, rat sarcoma viral oncogene homologue; RAF,
v-raf murine sarcoma viral oncogene homologue; MEK, MAPK/ERK activator
kinase; ERK, extracellular signal-regulated kinase), the PI3K-AKT pathway (PI3K,
phosphoinositide 3-kinase), the PLC-PKC pathway (PLC, phospholipase C-
PKC, protein kinase C) and the STATs (signal transducer and activator of
transcription) pathway (Figure 1). These signalings finally culminate in cell
proliferation, migration, adhesion, invasion, cell cycle progression and
differentiation[4, 12-14].
EGFR has been shown to play important roles in development. In genetically
engineered mouse models, mice lacking EGFR die within the first month of birth
and multiple developmental defects can be observed in mammary duct, skin,
2

Figure 1. The EGFR signaling. Schematic representation of the functional
domains of EGFR, the tyrosine (Y) phosphorylations induced by ligand stimulation
and the downstream signaling cascades activated by recruiting cytosolic signaling
molecules to the phospho-tyrosine residues. Red arrows indicate bindings
between the phospho-tyrosines and the cytosolic molecules.
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central nervous system, lung, pancreas and gastrointestinal tract[15-20]. EGFR
has also been linked to stem cell renewal and proliferation[21-26]. Besides,
aberrant EGFR activation caused by EGFR gene amplification, mutation and/or
ligand overexpression is involved in the pathogenesis and progression of various
cancer types, especially breast cancer, lung cancer and colon cancer[12, 27-36].

1.2 Regulation of EGFR signaling by post-translational modifications
Post-translation modifications (PTMs) play central roles in the activation and
regulation of EGFR signaling. As mentioned above, ligand-stimulated EGFR
tyrosine autophosphorylations are essential to transmit extracellular stimuli into
intracellular responses. Each of the phospho-tyrosines and its flanking amino acid
residues form a peptide motif to selectively bind the SH2 or PTB domains of one
or more cytosolic signaling molecules. Similarly, with very few exceptions, each of
the cytosolic signaling molecules binds EGFR through more than one
phospho-tyrosine with different affinities[37-40] (Figure 1). Given that different
ligand stimulations or dimerization partners can induce different tyrosine
phosphorylation patterns on EGFR[41-43]. This redundancy in binding sites
between phospho-tyrosines and cytosolic signaling molecules allows the
4

activation of various downstream signaling cascades to be combinatorially
regulated by different stimulation conditions or cellular contents[38, 39]. In
addition to the positive roles in initiating EGFR downstream signalings,
autophosphorylated tyrosine residues also mediate inhibitory mechanisms
against EGFR activity. One well-characterized example is Y1045, which serves as
a docking site for Cbl (Casitas B-cell lymphoma), the primary E3 ubiquitin ligase of
EGFR. Recruitment of Cbl to EGFR through phosphorylated Y1045 promotes
receptor ubiquitination and degradation, resulting in downregulation of EGFR
activity[44]. Receptor with defective Y1045 phosphorylation escapes from
Cbl-induced ubiquitination and degradation[45-47].
Many other kinases also involve in the EGFR signaling through directly
phosphorylating EGFR. Some of the best known include: growth
hormone-activated JAK2 (Janus kinase 2) can phosphorylate EGFR at Y1068 and
specifically trigger EGFR-mediated ERK activation [48]. Src phosphorylates
EGFR at Y845 and Y1101, resulting in enhanced receptor signaling[49].
Serine/threonine phosphorylation by PKC, ERK and CaMKII
(calmodulin-dependent protein kinase II) modulates receptor tyrosine kinase
activity and internalization[50-52].
5

Besides phosphorylation, EGFR is also subjected to non-phosphorylation
post-translational modifications. One of the well-known is N-glycosylation of the
EGFR extracellular domain, which is essential for the maturation and membrane
transport of nascent receptor, and for the ligand binding activity of mature surface
receptor[53-57]. Moreover, the E3 ubiquitin ligase Cbl-mediated ubiquitination and
neddylation have been demonstrated as a primary attenuation mechanism of
EGFR signaling. Both modifications coordinately serve as sorting signals to
promote lysosomal degradation of activated EGFR and control the duration of
EGFR activation[58-63]. Recently identified acetylation of EGFR further expands
the content of EGFR PTM network as acetylation was demonstrated to enhance
endocytosis or tyrosine phosphorylation of the receptor[64, 65].

1.3 Protein arginine methylation in regulating cellular processes
Protein arginine methylation is a post-translational modification that adds
one or two methyl groups to the guanidino nitrogen atoms of arginine. Methyl
groups can be added to the internal () or the terminal () nitrogen atoms. So far,
-NG-methylarginine residues have been observed only in Saccharomyces
cerevisiae. In eukaryotes, three types of methylarginine have been identified,
6

including -NG-monomethylarginines (MMA), -NG, NG-asymmetric
dimethylarginines (aDMA), and -NG, N'G-symmetric dimethylarginines (sDMA)
[66-68] (Figure 2).
Arginine is a positively charged amino acid important in mediating hydrogen
bonding and amino-aromatic interactions. Although methylation does not change
the overall charge of an arginine residue, addition of methyl groups removes
amino hydrogens that be involved in hydrogen bonds and increases steric
hindrance. Therefore, arginine methylation may inhibit intra- or inter-molecular
interactions. On the other hand, arginine methylation can also act as a positive
regulator of protein-protein interactions. The Tudor domain has been recognized
as a methyl-binding protein structure motif specifically recognizing di-methyl
arginines. Several Tudor domain-containing proteins have been shown to interact
with their binding partners in a methylarginine-dependent manner[69-71]. Besides
protein-protein interactions, arginine methylation may modulate protein function
through regulating the subcellular localization of targeting proteins[72-75].
Through these regulatory mechanisms, arginine methylation has been shown to
be involved in transcriptional regulation, RNA processing, signaling transduction
and DNA damage repair[67, 68, 76, 77].
7

Figure 2. Arginine methylation and the protein arginine methyltransferase
(PRMT) family. Monomethylarginine (MMA) can be generated by all types of
PRMTs. Type I and type II PRMTs further catalyze the formation of asymmetric
dimethylarginine (aDMA) and symmetric dimethylarginine (sDMA), respectively.
S-adenosyl methionine (AdoMet) is the methyl group donor and converted into
S-adenosyl homocysteine (AdoHcy) after reactions.
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1.4 Protein arginine methyltransferases (PRMTs), demethylase and
deiminase
Protein arginine methylation is mediated by enzymes of the protein arginine
N-methyltransferase (PRMT) family. All family members share a core arginine
methyltransferases region which catalyze the transfer of a methyl group from the
methyl donor, S-adenosyl methionine (AdoMet) to arginine[67, 68, 76-78]. PRMT
members are further classified into four major groups according to the type of
methylarginine they generate. Type I, II and III PRMTs methylate the terminal ()
guanidino nitrogen atoms. Type I and type II PRMTs both catalyze the formation of
MMA, and type I PRMTs further catalyze the production of aDMA, whereas type II
PRMTs catalyze the formation of sDMA. Type III PRMTs catalyze only MMA
(Figure 2). Besides, type IV PRMTs methylate the internal () guanidino nitrogen
atom of arginine[67, 68, 76, 77].
Currently, ten mammalian PRMTs have been identified within which PRMT1,
3, 4, 6 and 8 belong to type I PRMTs, whereas PRMT5, 7 and FBXO11 exhibit
type II enzymatic activity. In addition, PRMT7 also shows type III activity on certain
substrates. On the contrary, no activity has been demonstrated for PRMT2 and
PRMT9, and no type IV enzyme has been identified in mammals to date [67, 68,
9

77] (Figure 2). Proteins harboring GAR (glycine- and arginine-rich) or PGM
(proline-, glycine-, methionine-, arginine-rich) motifs are often candidate targets
for PRMTs[69, 79].
In contrast to the action of PRMTs, methylation of an arginine can be
removed by demethylase or deiminase. JMJD6 (Jumonji domain–containing 6
protein) is the only demethylase identified to data, which demethylates histone H3
at arginine 2 and histone H4 at arginine 3, and reverses methylated arginine back
to arginine[80]. Besides, the peptidyl arginine deiminase can block methylation on
an arginine residue by converting it to citrulline. PAD4 (peptidylarginine deiminase
4) deiminase has been shown to catalyze the deimination of both arginine and
monomethylarginine, but not dimethylarginine, to citrulline and prevent
dimethylation formation on histone H3 arginine 17 and histone H4 arginine 3 by
PRMT4 and PRMT1, respectively[81] (Figure 3).

1.5 PRMT5
PRMT5 was originally cloned as a JAK2-binding protein with type II arginine
methyltransferase activity[82, 83]. Subsequent investigations indicate that PRMT5
functions in various protein complexes localized to both the cytoplasm and the
10

Figure 3. Inhibition of arginine methylation by the peptidyl arginine
deiminase (PAD). PAD blocks arginine methylation by converting arginine or
monomethyl arginine (MMA) to citrulline.
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nucleus. Nuclear PRMT5 is linked to several roles in transcription regulation. It
forms complexes with the hSWI/SNF (human switch/sucrose non-fermenting)
chromatin-remodeling proteins BRG1 (Brahma-related gene 1) and BRM (Brahma)
to methylate histone H3 at arginine 8, resulting in the repression of tumor
suppressor genes ST7 (suppression of tumorigenicity 7) and NM23
(nonmetastatic 23) and promotion of a tumorigenic state in NIH3T3 cells[84]. It
also methylates histone H4 at arginine 3 to recruit DNA methyltransferase
DNMT3A (DNA cytosine methyltransferase 3A) for gene silencing[85]. Besides,
nuclear PRMT5-mediated arginine methylation of p53 disposes p53 to trigger
cell-cycle arrest rather apoptosis[86]. In the cytoplasm, PRMT5 is found in the
methylosome, where it methylates several spliceosomal Sm proteins to promote
the assembly and stability of the splicesome and regulate snRNP
(small nuclear ribonucleoprotein) biogenesis[87-89]. During the derivation of
embryonic stem cells, PRMT5 is upregulated in the cytosol and methylates
histone H2A at arginine 3 to maintain stem cell pluripotency[90]. In yeast model,
cytoplasmic PRMT5 also has been shown to inhibit cell cycle progression through
binding with cell cycle inhibitor cdc25p[91] and suppress the MAPK pathway by
inhibiting STE20p kinase[92].
12

Currently, little is known about the regulations of the expression, stability or
activity of PRMT5. Recent studies indicate that PRMT5 activation requires
PRMT5 homo-dimerization and association with a cofactor, Mep50 (methylosome
protein 50)[68]. Moreover, the subcellular location of Mep50 varies under different
physiological and pathological conditions[93-95]. These findings suggest that
PRMT5 activity may be regulated by the expression or subcellular distribution of
Mep50. In addition, tyrosine phosphorylation of PRMT5 by a JAK2 constitutively
active mutant JAK2V617F disrupts PRMT5-Mep50 association and impairs
PRMT5 methyltransferase activity[96]. Besides, the substrate specificity of
PRMT5 can be regulated by its binding partners. RioK1 (Rio kinase 1) and pICln
mutually exclusively bind with PRMT5. They complete for binding to PRMT5 and
coexist with PRMT5-Mep50 in two distinct protein complexes, in which they serve
as adapters to recruit different PRMT5 substrates. The RioK1-containing
PRMT5-Mep50 complex methylates the RNA-binding protein nucleolin and the
pICln-containing complex methylates the spliceosomal Sm proteins[97].

1.6 Hypothesis
Although protein arginine methylation and arginine methyltransferase have
13

been known since 1968[98, 99], the cellular processes affected by arginine
methylation only have begun to be elucidates in the last decade, and a growing
body of evidence suggests that methylation may parallel other PTMs in its role in
the regulation of various biological processes[67, 68, 76, 77, 100, 101]. Here, we
hypothesize that protein methylation may involve in the EGFR signaling, a
biological process extensively regulated by multiple PTMs. If this is the case,
identification and elucidation of the role of methylation in EGFR signaling will
comprise a new level of EGFR regulation.

14

CHAPTER 2

MATERIAL AND METHOD

2.1 Constructs, antibodies, reagents, and peptides
All GFP-PRMT plasmids were kindly provided by Dr. Mark T. Bedford.
PRMT3, PRMT5, and PRMT8 cDNAs were further subcloned into a modified
pCMV5 vector containing an N-terminal HA tag. Full-length EGFR cDNA was
cloned into a pCDNA3 vector. PRMT5 and EGFR intracellular domain (ICD,
amino acid 645-1186) were further subcloned into a modified pCMV5 vector
containing an N-terminal GST tag for the purification of recombinant protein.
EGFR R1175K and PRMT5 R368A mutagenesises were generated using the
QuickChange Site-Directed Mutagenesis Kit according to the manufacturer’s
protocol (Stratagene). Epidermal growth factor (EGF) and U0126 were purchased
from Sigma and Cell Signaling, respectively, and prepared according to the
manufacturer’s instructions. The following peptides were chemically synthesized
from QCB for antibody production in mice, dot blots, peptide competition assay,
and in vitro methylation assay. Unmodified peptide:
NH2-CAEYLRVAPQSSE-COOH; Methylated peptides:
NH2-CAEYL(monomethyl-R)VAPQSSE-COOH, NH2-CAEYL(symmetric
15

dimethyl-R)VAPQSSE-COOH and NH2-CAEYL(asymmetric
dimethyl-R)VAPQSSE-COOH. Histone H4 peptide with monomethyl R3 was
purchased from Abcam. Anti-EGFR (Ab-12, 1:5000) antibody from Thermo
Scientific and anti-EGFR (06-847, 1:5000) antibody from Millipore were used to
detect full-length EGFR and EGFR peptides, respectively. For detection of EGFR
tyrosine phosphorylations, antibody to phosphotyrosine (4G10, 1:5000) from
Millipore was used to detect total tyrosine phosphorylations, and site-specific
antibodies against phospho-Y845, Y992, Y1045, Y1068, Y1086, Y1148, and
Y1173 from Cell Signaling and Abcam were used (1:2000) to detect individual
phosphotyrosine. Antibodies to ERK (1:5000), SHP1 (1:2000) and SHC (1:5000)
from Millipore, antibodies to STAT3 (1:2000) and SOS (1:2000) from Santa Cruz,
and antibodies to AKT (1:2000), PLC-(1:2000), phospho-ERK (1:5000),
phospho-AKT (1:2000), phospho-STAT3 (1:2000), phospho-PLC- (1:2000) and
Grb2 (1:2000) from Cell Signaling were used to detect the EGFR downstream
pathways. Anti-PRMT5 (1:5000) and anti-tubulin (1:5000) antibodies were from
Sigma. Anti-GFP (1:5000) antibody was from Thermo Scientific. For
immunofluorescence staining, antibodies were diluted 1:200. For
immunoprecipitation, 5g of anti-EGFR (Ab-13, Thermo Scientific), anti-Grb2,
16

anti-SHC or anti-SOS antibodies were used per 1mg of total protein in 1 ml of cell
lysates.

2.2 In vivo methylation assay
For in vivo methylation of EGFR, a procedure, modified from the method
described by Qing Liu et al.[102], was used. A431 cells were incubated 1 hr in
Dulbecco’s modified Eagle’s medium (DMEM) (GIBCO) supplemented with 10%
FBS, 100 g/ml cycloheximide (Sigma), and 40 g/ml chloramphenicol (Sigma).
Then, cells were washed twice with methionine-depleted DMEM (GIBCO) and
incubated in the same medium containing 10 Ci/ml L-[methyl-3H]methionine
(Amersham Biosciences), 10% dialyzed FBS (GIBCO), 100 g/ml cycloheximide,
and 40 g/ml chloramphenicol. After labeling for 5 hr, endogenous EGFR was
immunopurified and analyzed by SDS-PAGE. 3H-methyl incorporation was
visualized by fluorography. For monitoring the effect of protein synthesis inhibitors,
A431 cells were also labeled with 10 Ci/ml L-[35S]methionine (MP Biomedicals)
using a procedure almost exactly the same as the one described above, with or
without protein synthesis inhibitors. After labeling, whole-cell lysates were
prepared, analyzed by SDS-PAGE, and detected by autoradiography.
17

2.3 In vitro methylation assay
HA-PRMT3, HA-PRMT5, and HA-PRMT8 were expressed in HEK293 cells
and immunopurified using HA-agarose (Sigma). The enzymes immobilized on the
beads were then incubated with unmodified peptide (50 g) in the presence of 2.2
Ci S-adenosyl-L-[methyl-3H]methionine (85 Ci/mmol from a 0.55 mCi/ml stock
solution) (MP Biomedicals) for 1 hr at 30℃ in a final volume of 50 l of
phosphate-buffered saline. One microgram of peptide was spotted onto PVDF
membranes and detected using anti-EGFR or anti-EGFR me-R1175 antibodies.
Five micrograms of peptide were spotted onto P81 papers, washed, and counted
by liquid scintillation.
In vitro methylation assay was also performed as following. GST-PRMT5 and
GST-EGFR (ICD) were expressed in HEK293 cell and purified using glutathione
resin (GE Healthcare). GST-PRMT5 and GST-EGFR (ICD) proteins were
incubated in the presence of 2.2 Ci S-adenosyl-L-[methyl-3H]methionine (85
Ci/mmol from a 0.55 mCi/ml stock solution) for 1 hr at 30℃ in a final volume of 50
l of phosphate-buffered saline. Subsequently, samples were analyzed by
SDS-PAGE and EGFR methylation was detected using fluorography and
18

anti-EGFR me-R1175 antibody.

2.4 In vitro kinase assay
A procedure, modified from the method described by Jaeho Lee et al.[103],
was used. HA-EGFR was expressed in HEK293 cells and immunopurified using
HA-agarose. The EGFR proteins immobilized on the beads were then incubated
with unmodified or monomethylated peptides (50 g) in a total volume of 50 l of
reaction buffer containing 5 mM HEPES (pH 7.4), 50 M Na3VO4, 5 mM MnCl2, 2
mM MnCl2, 40 g/ml BSA, 250 mM ammonium sulfate, 25 M ATP, and 62.5
Ci/ml [-32P]ATP (MP Biomedicals). Reactions were performed at 30℃ and
stopped using 8.5% phosphoric acid. One microgram of peptide was spotted onto
PVDF membranes and detected using anti-EGFR or anti-EGFR p-Y1173
antibodies. Five micrograms of peptide were spotted onto P81 papers, washed,
and counted by liquid scintillation.

2.5 siRNA transfection and siRNA-resistant mutant of PRMT5
Cells were transfected individually with three PRMT5 siRNA oligonucleotides
(#1: 5’-UGGCACAACUUCCGGACUUUU-3’, #2:
19

5’-CAACAGAGAUCCUAUGAUU-3’ or #3: 5’-CGAAAUAGCUGACACACUA-3’) or
two EGFR siRNA oligonucleotides (#1: 5’-CAAAGUGUGUAACGGAAUA-3’ or #2:
5’-CCAUAAAUGCUACGAAUAU-3’) with DharmaFECT 1 (Dharmacon), and used
for experiments 96 hr after transfection. A non-targeting siRNA
(5’-UGGUUUACAUGUCGACUAA-3’) was used as control. To rescue the
phenotype of PRMT5 siRNA, an siRNA-resistant mutant of PRMT5 (RR-PRMT5)
was created by substituting five nucleotides in the PRMT5 siRNA #1 targeting
region (C570T, C573T, C576T, C577A and G579A).

2.6 Mass spectrometry
EGFR was isolated by immunoprecipitation with anti-EGFR antibody and
analyzed by SDS-PAGE. The protein band corresponding to EGFR was excised
and subjected to in-gel digestion with trypsin. After being isolated from gel,
samples were analyzed by nanoelectrospray mass spectrometry which was
performed using an Ultimate capillary LC system (LC Packings, Amsterdam, The
Netherlands) coupled to a QSTARXL quadrupole-time of flight (Q-TOF) mass
spectrometer (Applied Biosystem/MDS Sciex, Foster City, CA).
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2.7 Confocal microscopy analysis
Cultured cells were washed three times with PBS, fixed in 4%
paraformaldehyde for 15 min, permeabilized with 0.5% Triton X-100 for 15 min,
and incubated with 5% bovine serum albumin for 1 h. Cells were then incubated
with the primary antibodies overnight at 4°C. Cells were washed with PBS and
then further incubated with the appropriate secondary antibody diluted at 1:500
and tagged with fluorescein isothiocyanate (FITC), Texas red, or Alexa 647 [104]
for 45 min at room temperature. Nuclei were stained with DAPI before mounting.
Confocal fluorescence images were captured using a Zeiss LSM710 laser
microscope. In all cases, optical sections through the middle planes of the nuclei
as determined using nuclear counterstaining were obtained.

2.8 Cell proliferation assay
Cells (5 x 103 cells per well) were seeded in 96-well plates, and relative cell
amounts were determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) colorimetric method on a daily basis. MTT (Sigma) at 1
mg/ml was added to each well. After 2-hr incubation, the medium was removed,
and the MTT was solubilized in 100 l of DMSO. The absorbance was measured
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at 570 nm, and the relative proliferation index for each day was determined using
the absorbance at day 0 as the standard.

2.9 Migration and invasion assay
Cell migration and invasion were analyzed using Biocoat Control inserts and
Biocoat Matrigel invasion chambers (BD Biosciences), respectively. Cells (2 x 105)
in DMEM medium with 0.1% FBS were added to the upper chamber and allowed
to penetrate a porous (8 m), uncoated membrane or a Matrigel-coated
membrane to the bottom chamber containing DMEM medium with 10% FBS.
Cells on the top surface of the membrane were removed 72 hr after incubation,
and the remaining cells on the bottom surface were fixed with 4%
paraformaldehyde, stained with 0.5 % crystal violet, and counted from four
random fields of each membrane using a bright-field microscope. The average
cell number per field for each membrane was used to calculate the mean and s.d.
for triplicate membranes. Migration value is shown as “number of migrated cells
per field”. Invasion value is reported as the “invasion index = number of invaded
cells per field / number of migrated cells per field”.
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2.10 Mouse model
In vivo cell growth was analyzed in an orthotopic breast cancer mouse
model[105]. Briefly, cells (5 x 106 cells) were injected into the mammary fat pads
of nude mice, and the tumor volumes were measured weekly.

2.11 Statistics
All quantitative results are presented as the mean and s.d. of independent
experiments. Statistical differences between two groups of data were analyzed by
Student's t-test.

23

CHAPTER 3

EGFR R1175 IS MONOMETHYLATED

3.1 EGFR is methylated in vivo
To determine whether EGFR is a target of methylation, we performed an in
vivo methylation assay in which cells were metabolically labeled with
L-[methyl-3H]methionine in the presence of protein synthesis inhibitors (Figure 4A,
lanes 1-6), and endogenous EGFR proteins were immunopurified, followed by
analysis with fluorography. We observed a radioactive signal corresponding to the
size of EGFR in the immuno-products of anti-EGFR antibody (Figure 4A, lane 2)
but not in those of the control antibody (Figure 4A, lane 1). Simultaneously, we
also labeled cells with L-[35S]methionine to monitor the activity of protein synthesis
inhibitors (Figure 4A, lanes 7-10). No L-[35S]methionine incorporation was
detected in the presence of the inhibitors (Figure 4A, compare lane 10 to lane 9),
indicating that the radiolabeling in lane 2 was resulted from post-translational
modification, rather than from translational incorporation. Taken together, these
results suggest that endogenous EGFR is a target of protein methylation.

3.2 EGFR R1175 is monomethylated
24

Next, we used mass spectrometry analysis to identify methylation site(s) of
endogenous EGFR immunopurified from cells and result shows that EGFR R1175
is monomethylated (Figure 4B). This finding further supports EGFR methylation
and indicates methylation of R1175.

3.3 Generation and characterization of the EGFR monomethylated-R1175
antibody
To assist detection of EGFR R1175 monomethylation, we generated a
polyclonal antibody against a synthetic methylated EGFR peptide antigen. This
antibody specifically recognized a monomethylated EGFR peptide (amino acid
1171-1182), in which R1175 residue is monomethylated, but not unmodified and
dimethylated peptides (Figure 5A). In addition, this antibody only recognized
ectopic full-length EGFR wild type (wt) and not methylation-site mutant (R1175K)
in cells (Figure 5B). In peptide competition assays, only the monomethylated
EGFR peptide neutralized the activity of antibody (Figure 5C). Therefore, this
antibody is capable of specifically recognizing R1175-methylated EGFR. In
addition to exogenous EGFR proteins, this antibody is suitable for endogenous
EGFR detection (Figures 5D and 5E). Methylated EGFR is mainly located at the
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cell membrane region.
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Figure 4. EGFR R1175 is monomethylated
A. In vivo methylation of EGFR. A431 cells were metabolically labeled with
L-[methyl-3H]methionine (left panel) or L-[35S]methionine (right panel) in the
presence or absence of protein synthesis inhibitors, as indicated.
Immunoprecipitates of EGFR or control antibodies from
L-[methyl-3H]methionine-labeled cells were analyzed by fluorography (lanes 1 and
2), coomassie blue staining (lanes 3 and 4), or western blotting with EGFR
antibody (lanes 5 and 6). Whole-cell lysates of L-[35S]methionine-labeled cells
were analyzed by coomassie blue staining (lanes 7 and 8) or autoradiography
(lanes 9 and 10).
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Figure 4. EGFR R1175 is monomethylated
B. Mass spectrometry analysis of endogenous EGFR immunopurified from A431
cells.
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Figure 5. Generation and characterization of the antibody specifically
recognizing EGFR R1175 methylation
A. Amino acid sequence of peptides corresponding to the EGFR 1171-1182
region in which R1175 is unmodified, monomethylated or dimethylated. Different
amounts of peptides were spotted on PVDF membranes and detected by
anti-EGFR (Millipore #06-847) or anti-EGFR me-R1175 antibodies.
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Figure 5. Generation and characterization of the antibody specifically
against EGFR R1175 methylation
B. Western blot analysis of exogenous EGFR in HEK293 cells transfected with
control vector, EGFR (wt) or EGFR (R1175K).
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Figure 5. Generation and characterization of the antibody specifically
against EGFR R1175 methylation
C. Western blot analysis of exogenous EGFR in HEK293 cells transfected with
empty vector, EGFR (wt) or EGFR (R1175K). Anti-EGFR me-R1175 antibody was
pre-incubated with peptides, as indicated prior to use.

D. Western blot analysis of endogenous EGFR in MDA-MB-468 cells transfected
with control or EGFR siRNAs.
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Figure 5. Generation and characterization of the antibody specifically
against EGFR R1175 methylation
E. Confocal microscopy analysis of MDA-MB-468 cells stained with total
endogenous EGFR (red), me-R1175 (green) and DAPI (blue).
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CHAPTER 4

PRMT5 METHYLATES EGFR R1175 IN VITRO AND IN VIVO

4.1 PRMT5 interacts with EGFR and methylates R1175
Members of the protein arginine methyltransferase (PRMT) family are the
only enzymes responsible for protein arginine methylation[67]. To identify the
upstream enzyme responsible for EGFR R1175 methylation, we screened the
interaction between EGFR and several PRMT family members by using
co-immunoprecipitation assays and found that EGFR bound with PRMT5 and
PRMT8 (Figure 6A). Next, in vitro methylation assays were used to determine
whether PRMT5 and/or PRMT8 could methylate EGFR. The unmodified EGFR
peptide was incubated with affinity-purified PRMT3, PRMT5 or PRMT8 in the
presence of S-adenosyl-L-[methyl-3H]methionine as a methyl donor and
methylation was detected using R1175 methylation-specific antibody and
scintillation counting. We observed that PRMT5 and PRMT8, but not PRMT3,
methylated R1175 (Figure 6B). In human tissues, PRMT5 is ubiquitously
expressed while PRMT8 is restricted in the brain [103, 106, 107]. In human breast
cancer cell, EGFR is mainly associated with the cell membrane region, where
some PRMT5 is also found (Figure 6C). Suppression of endogenous PRMT5
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expression by short interfering RNAs (siRNAs) decreased R1175 methylation and
reintroduction of an siRNA-resistant PRMT5 mutant (RR-PRMT5) rescued the
effect of siRNA (Figure 6D). Collectively, these data indicate that PRMT5 is an
enzyme responsible for EGFR R1175 methylation. Using in vitro methylation
assays with recombinant EGFR proteins as substrates, we further confirmed that
PRMT5 methylates EGFR only at R1175 residue (Figure 6E).

4.2 EGF stimulation and EGFR kinase activity are not required for R1175
methylation
Similarly to the interactions between other PRMTs with their substrates[77,
78, 106], PRMT5 binds with EGFR mainly through its catalytic core domain
(Figure 7). Moreover, the PRMT5-EGFR binding (Figure 8, top panel) and the
R1175 methylation status (Figure 8, bottom panel) are independent of EGF
stimulation, indicating that EGF stimulation and EGFR kinase activity are not
required for R1175 methylation.
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Figure 6. PRMT5 interacts with EGFR and methylates R1175
A. Western blot analysis of exogenous EGFR and PRMTs in the input and
anti-EGFR immunoprecipitates from HEK293 cells transfected with EGFR and
GFP-PRMTs, as indicated.
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Figure 6. PRMT5 interacts with EGFR and methylates R1175
B. In vitro methylation assay of unmodified EGFR peptide by immunopurified
HA-PRMT3, 5, or 8. Methylation of peptides was detected by western blotting (top
panel) and scintillation counting (bottom panel). Error bars represent s.d. (n = 3).
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Figure 6. PRMT5 interacts with EGFR and methylates R1175
C. Confocal microscopy analysis of MDA-MB-468 cells stained with endogenous
EGFR (red), PRMT5 (green) and DAPI (blue).
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Figure 6. PRMT5 interacts with EGFR and methylates R1175
D. Western blot analysis of endogenous EGFR and total PRMT5 of the
MDA-MB-468 cells in which endogenous PRMT5 was knocked down by three
PRMT5 siRNAs (lane 1-4) and then rescued with an siRNA-resistant PRMT5
mutant (RR-PRMT5) (lane 5).
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Figure 6. PRMT5 interacts with EGFR and methylates R1175
E. In vitro methylation assay of EGFR intracellular domain (ICD) wild type (wt) or
R1175K mutant by PRMT5 wild type (wt) or inactive mutant (R368A). Methylation
of EGFR (ICD) was detected by fluorography and western blotting using
anti-EGFR me-R1175 antibody.
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Figure 7. PRMT5 associates with EGFR through the catalytic core domain
Left panel: Schematic representation of the PRMT5 domain structure containing
catalytic core, pre-core and post-core domains. PRMT5 truncation mutants
without pre-core domain, post-core domain or both domains are assigned as N,
C or NC, respectively. Arabic numbers indicate amino acid residues. Right
panel: Western blot analysis of exogenous EGFR and PRMT5 in the input and
anti-EGFR immunoprecipitates from HEK293 cells transfected with EGFR and
various PRMT5 truncation mutants.
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Figure 8. EGF stimulation and EGFR kinase activity are not required for
R1175 methylation
Western blot analysis of endogenous EGFR and PRMT5 in the input (bottom
panel) and immunoprecipitates of indicated antibodies (top panel) from
EGF-stimulated and siRNA-transfected MDA-MB-468 cells.
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CHAPTER 5

R1175 METHYLATION NEGATIVELY MODULATES EGFR

FUNCTIONALITY

5.1 Suppression of R1175 methylation promotes EGFR-mediated cell
proliferation, migration, and invasion
As mentioned in the introduction, multiple lines of the EGFR downstream
signalings ultimately culminate in cell proliferation, migration, invasion, and
tumorigenicity[14, 39, 40]. To investigate if EGFR R1175 methylation participates
in the EGFR functionality, we created three stable transfectants of human MCF7
breast cancer cells with EGFR (wt), EGFR (R1175K), or empty vector (designated
as MCF7-EGFR [wt], MCF7-EGFR [R1175K], and MCF7-vector, respectively) for
serial functional studies (Figure 9A). First, to evaluate their in vitro cell growth
abilities, cells were cultured in DMEM supplemented with 10% FBS and relative
cell amounts were determined by the MTT colorimetric method on a daily basis.
The results showed MCF7-EGFR (R1175K) proliferated faster than MCF7-EGFR
(wt), as compared with MCF7-vector control (Figure 9A). Moreover, we used an
orthotopic tumor cell growth model to assay the in vivo cell growth of these cells.
Cells were injected into the mammary fat pads of nude mice and the tumor
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volumes were measured weekly. Consistently, we found that MCF7-EGFR
(R1175K) cells were more efficient than MCF7-EGFR (wt) and MCF7-vector cells
at inducing mammary tumor formation (Figure 9B). On the other hand, the cell
motility or invasiveness of these cells was analyzed using a Transwell chamber
system with a porous, uncoated membrane or a Matrigel-coated membrane
respectively. The cells placed in the upper chamber were induced to migrate
across 8.0 m membrane pores to the lower chamber in response to the
chemoattractant. In cell motility, we observed EGFR (R1175K)-expressing cells
migrated more efficiently than the control cells (220.2  46.6% of MCF7-vector
control), even though MCF7-EGFR (wt) had only slightly positive effects on cell
migration (132.8  24.8% of MCF7-vector control) under experimental condition
(Figure 9C, left panel). In invasion assay, no significant effect was observed in
MCF7-EGFR (wt) cells. In contrast, MCF7-EGFR (R1175K) cells exhibited
significantly increased invasion ability (254.4  80.1% of MCF7-vector control)
(Figure 9C, right panel). Taken together, these results suggest an inhibitory role of
R1175 methylation in the EGFR functionality.
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Figure 9. Suppression of R1175 methylation promotes EGFR-mediated cell
proliferation, migration, and invasion
A. Western blot analysis of MCF7 stable transfectants expressing EGFR (wt),
EGFR (R1175K), or empty vector. In vitro cell proliferation rates were assayed
using the MTT colorimetric method. Error bars represent s.d. (n = 5).
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Figure 9. Suppression of R1175 methylation promotes EGFR-mediated cell
proliferation, migration, and invasion
B. In vivo cell proliferation was measured using an orthotopic breast cancer
mouse model. Error bars represent s.d. (n = 10).
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Figure 9. Suppression of R1175 methylation promotes EGFR-mediated cell
proliferation, migration, and invasion
C. Migration assay (left) and invasion assay (right) of these stable transfectants.
Statistical analysis was performed with Student’s t-test. Error bars represent s.d.
(n = 3).
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CHAPTER 6

R1175 METHYLATION CROSSTALKS WITH Y1173

PHOSPHORYLATION

6.1 R1175 methylation upregulates ligand-stimulated EGFR
autophosphorylation at Y1173
Regulatory crosstalk usually occurs between two closely spaced
post-translational modifications. To further explore how R1175 methylation is
involved in EGFR functionality, we noticed that R1175 residue is close to several
tyrosine residues that are autophosphorylated during EGFR activation. This gives
us a clue that R1175 methylation might regulate EGFR through crosstalk with
these tyrosine phosphorylations. Thus, we activated EGFR (wt) and EGFR
(R1175K) with EGF and then compared their tyrosine phosphorylation status
using several site-specific antibodies against phospho-Y845, Y992, Y1045,
Y1068, Y1086, Y1148, and Y1173. Interestingly, compared with EGFR (wt), EGFR
(R1175K) got fully phosphorylated at all tyrosine residues tested except Y1173
(Figure 10A). To rule out the possibility that the change of Y1173 phosphorylation
was caused by protein conformational misfolding of R1175K mutagenesis, EGFR
R1175 methylation status was also manipulated by using multiple PRMT5 siRNAs
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as a comparison. Consistently, PRMT5 knockdown specifically inhibited
EGF-induced phosphorylation at Y1173, and not other tyrosine residues (Figure
10B). These results indicate that R1175 methylation positively modulates Y1173
phosphorylation.

6.2 R1175 methylation upregulates Y1173 phosphorylation by EGFR in vitro
EGFR Y1173 phosphorylation is mediated by EGFR itself. Thus, we further
check whether R1175 methylation affects Y1173 phosphorylation by in vitro
kinase assays in which EGFR peptides with or without R1175 monomethylation
were used as substrates for EGFR. Results show EGFR phosphorylated the
monomethylated peptide more efficiently than the unmodified peptide (Figure 11),
further supporting previous finding that R1175 methylation upregulates Y1173
phosphorylation.
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Figure 10. R1175 methylation upregulates ligand-stimulated EGFR
autophosphorylation at Y1173
A. Left panel: Western blot analysis of exogenous EGFR in EGF-stimulated
MCF7-EGFR (wt) and MCF7-EGFR (R1175K) stable transfectants. Right panel:
Densitometry of phospho-EGFR Y1173 (p-Y1173) blot. Error bars represent s.d.
(n = 3).
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Figure 10. R1175 methylation upregulates ligand-stimulated EGFR
autophosphorylation at Y1173
B. Left panel: Western blot analysis of endogenous EGFR in EGF-stimulated
MDA-MB-468 cells transfected with control or PRMT5 siRNA #1. Right panel:
Densitometry of phospho-EGFR Y1173 (p-Y1173) blot. Error bars represent s.d.
(n = 3).
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Figure 11. R1175 methylation upregulates Y1173 phosphorylation by EGFR
in vitro
In vitro kinase assay of unmodified and monomethylated EGFR peptides by
immunopurified EGFR proteins. Phosphorylation of peptides was detected by
western blotting using anti-EGFR p-Y1173 antibody (top panel) and scintillation
counting (bottom panel). Error bars represent s.d. (n = 3).

51

CHAPTER 7

CROSSTALK BETWEEN R1175 METHYLATION AND Y1173

PHOSPHORYLATION RESULTS IN DOWNREGULATION OF ERK
ACTIVATION

7.1 Suppression of R1175 methylation inhibits SHP1 recruitment by EGFR
During EGFR activation, phospho-Y1173 is one of the binding sites for the
cytosolic signaling molecules SHC and Grb2 to elicit downstream ERK
activation[108-110]. Phospho-Y1173 also serves as the major docking site for
SHP1, an SH2 domain-containing protein tyrosine phosphatase. In contrast to the
effect of SHC and Grb2 binding, recruitment of SHP1 to EGFR leads to
attenuation of EGFR-dependent ERK activation[111]. Since R1175 methylation
positively regulates Y1173 phosphorylation, we were motivated to investigate
whether it modulates the binding between EGFR and these cytosolic molecules.
Using a co-immunoprecipitation assay, we found that downregulation of R1175
methylation by R1175K mutagenesis or by PRMT5 siRNA treatment inhibited only
EGFR-SHP1 binding, and not EGFR-Grb2 and EGFR-SHC associations (Figures
12A and 12B), suggesting that R1175 methylation improves SHP1 binding to
EGFR and may inhibit EGFR-mediated ERK activation.
52

7.2 Suppression of R1175 methylation prolongs EGFR-mediated ERK
activation
We also studied the effect of EGFR R1175 methylation on the four major
EGFR downstream pathways by monitoring the activation of key signaling
molecules, including ERK1 (p-ERK1 T202/Y204) and ERK2 (p-ERK2 T185/Y187)
in the RAS-RAF-MEK-ERK module, AKT (p-AKT S473) in the PI3K-AKT module,
PLC-1 (p-PLC-1 T783) in the PLC--PKC module, and STAT3 (p-STAT3 T705)
in the STATs module. In line with previous results, we observed that inhibition of
R1175 methylation affected only EGFR-mediated activation of ERK, and not AKT,
PLC- or STAT3 (Figures 13A and 13B). In EGFR (wt) cells, upon EGF stimulation,
ERK activation was transiently upregulated and then rapidly deactivated. In
contrast, ERK activation lasted longer when EGFR R1175 methylation was
downregulated by R1175K mutagenesis or by PRMT5 siRNA transfection (Figures
13A and 13B, compare even lanes and odd lanes). These results show that
R1175 methylation specifically inhibits EGFR-mediated ERK activation. In
supporting of this notion, ERK inhibitor treatment diminished the enhanced cell
growth, migration, and invasion abilities of MCF7-EGFR (R1175K) cells (Figures
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14A and 14B).
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Figure 12. Suppression of R1175 methylation inhibits SHP1 recruitment by
EGFR
A. Left panel: Western blot analysis of EGFR, SHP1, Grb2 and SHC in the input
and anti-EGFR immunoprecipitates from EGF-stimulated MCF7-EGFR (wt) and
MCF7-EGFR (R1175K) stable transfectants. Right panel: Densitometry of
EGFR-bound SHP1 blot. Error bars represent s.d. (n = 3).
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Figure 12. Suppression of R1175 methylation inhibits SHP1 recruitment by
EGFR
B. Left panel: Western blot analysis of endogenous EGFR, PRMT5, SHP1, Grb2
and SHC in the input and anti-EGFR immunoprecipitates from EGF-stimulated
MDA-MB-468 cells transfected with control or PRMT5 siRNA #1. Right panel:
Densitometry of EGFR-bound SHP1 blot. Error bars represent s.d. (n = 3).
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Figure 13. Suppression of R1175 methylation prolongs EGFR-mediated ERK
activation
A. Left panel: Western blot analysis of endogenous ERK, PLC-, STAT3 and AKT
in EGF-stimulated MCF7-EGFR (wt) and MCF7-EGFR (R1175K) stable
transfectants. Right panel: Densitometry of phospho-ERK (p-ERK) blot. Error bars
represent s.d. (n = 3).
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Figure 13. Suppression of R1175 methylation prolongs EGFR-mediated ERK
activation
B. Left panel: Western blot analysis of endogenous EGFR, PRMT5, ERK, PLC-,
STAT3 and AKT in EGF-stimulated MDA-MB-468 cells transfected with control or
PRMT5 siRNA #1. Right panel: Densitometry of phospho-ERK (p-ERK) blot. Error
bars represent s.d. (n = 3).

58

Figure 14. ERK inhibitor treatment impairs the enhanced cell growth,
migration, and invasion abilities of MCF7-EGFR (R1175K) cells
A. In vitro cell proliferation of MCF7-EGFR (wt), MCF7-EGFR (R1175K), and
MCF7-vector cells were performed in the presence or absence of the ERK
inhibitor U0126. Error bars represent s.d. (n = 3).
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Figure 14. ERK inhibitor treatment impairs the enhanced cell growth,
migration, and invasion abilities of MCF7-EGFR (R1175K) cells
B. Migration (left) and invasion (right) assays of MCF7-EGFR (wt), MCF7-EGFR
(R1175K), and MCF7-vector cells were performed in the presence or absence of
the ERK inhibitor U0126. Error bars represent s.d. (n = 3).
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CHAPTER 8

SUMMARY OF CHAPTER 3 TO 7 AND DISCUSSION

We observe that PRMT5-mediated EGFR R1175 methylation (Figures 4, 5
and 6) upregulates EGF-induced EGFR autophosphorylation at Y1173 (Figures
10 and 11). This modification crosstalk positively modulates EGFR-SHP1 binding
(Figure 12). In line with the published literatures[111], the increased EGFR-SHP1
binding results in suppression of EGFR-mediated ERK activation (Figure 13).
Accordingly, the methylation defective mutant, EGFR (R1175K), increases its
activity to promote cell proliferation, migration, invasion and tumorigenicity (Figure
9). Thus, we propose a new link between arginine methylation and tyrosine
phosphorylation regulate EGFR functionality. This regulatory mechanism is
significant for the following reasons. First, it indicates that EGFR methylation
could differentially regulate the activation of EGFR downstream pathways. We
might expect that any signaling event leading to a change in R1175 methylation
status would specifically modulate the EGF-EGFR-ERK signaling axis. Second, it
suggests EGFR might contain a protein modification code, which is reminiscent of
the histone code composed of abundant cross-regulated histone
modifications[112, 113]. In addition to R1175 methylation, seven potential lysine
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and arginine methylation sites were also identified in the kinase domain and
C-terminal tail of EGFR (Figure 15A). In the protein primary sequence, some of
them are close to, or even overlap with, other known modifications (Figure 15B).
Further study of individual methylation and their interrelationships with other
modifications would expand our knowledge of the EGFR signaling network. In
addition to EGFR, the current study may also open an avenue to understand the
regulation of other receptor tyrosine kinases by arginine methylation.
Our results suggest that EGFR Y1173 phosphorylation has a suppressive
effect on ERK signaling. Previous literature gave phospho-Y1173 two opposite
roles in EGFR-mediated ERK activation and indicated that phospho-Y1173 may
coact with phospho-Y992 ,Y1068, Y1086 and Y1148 to activate ERK signaling
through recruiting SHC and Grb2[108-110, 114], or may work alone to inhibit ERK
activation through SHP1 binding[111]. However, to the best of our knowledge, the
interrelationships between these two groups of proteins and phospho-Y1173 have
not been well-characterized. Here, we first demonstrate that EGFR recruits these
two groups of signaling molecules in a time-dependent manner (Figure 12). Upon
EGF stimulation, SHC and Grb2 bind to EGFR immediately while SHP1 is
recruited to EGFR only at the later stage (~30 min later after stimulation).
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Downregulation of phospho-Y1173 only suppresses the recruitment of SHP1 but
not SHC and Grb2 (Figure 12). These results indicate that the major function of
phospho-Y1173 is recruiting SHP1 to deactivate ERK at the later stage of EGFR
activation instead of recruiting SHC and Grb2 for ERK activation, which, as
mentioned above[108-110, 114], is coregulated by multiple phosphotyrosine
residues. The minor influence of Y1173 phosphorylation on SHC and Grb2
recruitment could be due to the redundancy in both specificity and function of the
different EGFR phosphorylation sites[38, 39]. To further address the role of
phospho-Y1173 in ERK activation, we generated a MCF7-EGFR (Y1173F) stable
transfectant and found that it exhibited higher proliferation and tumor formation
abilities than the MCF7-EGFR (wt) cells (Figures 16A, 16B and 16C), supporting
the suggestion that Y1173 phosphorylation plays a suppressive role in EGFR
functionality.
The association of SHP1 with EGFR results in suppression of
EGFR-mediated ERK activation. However, present knowledge has different
interpretations of the action of SHP1 on the EGFR signaling such that SHP1
binding to the EGFR can cause an overall decrease in tyrosine phosphorylation
status of the receptor and attenuation of the receptor signaling both in transient
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coexpression systems and in stably SHP1-transfected cells[111, 115, 116].
However, other studies have shown that repression of endogenous SHP1
expression by SHP1 siRNA does not affect full EGFR tyrosine
phosphorylation[117]. This contradiction raises question of how endogenous
SHP1 is involved in the EGFR signaling regulation. To clarify this issue, we
knocked down endogenous SHP1 expression by SHP1 siRNA and examined its
effect on EGF-stimulated EGFR phosphorylation and downstream signaling
activation (Figure 17A). The results show that SHP1 knockdown extends ERK
activation and, in line with previous studies, does not affect the EGFR tyrosine
phosphorylation status, suggesting that endogenous SHP1 may dephosphorylate
other molecules rather than EGFR to attenuate ERK activation.
EGFR activates ERK through EGFR-SHC-Grb2-SOS-Ras-RAF-MEK-ERK
pathway. Upon EGF stimulation, SHC-Grb2-SOS complex is recruited to EGFR. It
has been reported that these three molecules are subject to tyrosine
phosphorylation[118-120]. Next, we tested whether they are potential targets of
SHP1. We found EGF stimulation induces tyrosine phosphorylation of SHC and
SOS and knockdown of endogenous SHP1 can extend the phosphorylation status
of SOS (Figure 17B), suggesting SOS may be a potential target of endogenous
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SHP1 to reduce the activity of ERK. Given that phospho-Y1173 is the major
binding site of SHP1, we further tested whether Y1173 is involved in the regulation
of SOS tyrosine phosphorylation and found SOS phosphorylation status lasted
longer in the EGFR (Y1173F) cells than in the EGFR (wt) cells (Figure 17C).
Taken together, these data imply that phospho-Y1173 recruits endogenous SHP1
to attenuate ERK activation through reducing the phosphorylation of SOS, rather
than EGFR. Moreover, a similar pattern also could be observed in the EGFR
(R1175K) cells (Figure 17C), further supporting that R1175 methylation
downregulates ERK activation through enhancing Y1173 phosphorylation.
In this study, we found that EGFR R1175 methylation status is consistent
during EGF stimulation, raising question of how EGFR R1175 methylation can be
regulated. During our manuscript preparation, other studies indicate that the
methyltransferase activity of PRMT5 is controlled by Mep50. Mep50 is first
identified as an interacting protein of PRMT5 from a yeast-two hybrid screening
and subsequent studies show that Mep50 binding to PRMT5 is required for the
methyltransferase activity of PRMT5[68, 121]. Moreover, Mep50 has different
subcellular distribution patterns at various pathological stages of breast
cancer[122]. In malignant breast epithelia, Mep50 prefers nuclear localization,
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whereas in their benign counterparts, Mep50 is located at cytoplasm. Cytoplasmic
Mep50 has been linked to cell growth inhibition[122], but the mechanism is
unclear. As our results indicate PRMT5 methylates EGFR and suppresses
EGFR-mediated cell growth, it is reasonable to predict that cytoplasmic Mep50
may inhibit cell growth through upregulating PRMT5-mediated EGFR methylation.
To verify this hypothesis, we first tested whether cytoplasmic Mep50 is involved in
EGFR methylation. Following the method used in the original study[122], we
observed that NES (nuclear exporting signal)-fused Mep50, rather than NLS
(nuclear localization signal)-fused Mep50, increased EGFR R1175 methylation in
human breast cancer cell (Figure 18A), suggesting cytoplasmic Mep50 is involved
in EGFR R1175 methylation. Next, we evaluated the effect of EGFR methylation
in cytoplasmic Mep50-mediated cell growth suppression and found that
MCF7-EGFR (wt) cells were more susceptible than MCF7-EGFR (R1175K) cells
to NES-Mep50-induced cell growth arrest (Figure 18B), implying cytoplasmic
Mep50 may suppress cell growth through upregulating EGFR R1175 methylation.
Taken together, these preliminary data imply that the subcellular distribution of
Mep50 is a regulatory factor for EGFR R1175 methylation and future work will be
directed towards elucidation of the role of EGFR methylation at different
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pathological stages of breast cancer.
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Figure 15. Summary of EGFR post-translational modifications
A. Mass spectrometry identification of EGFR methylation sites. In addition to
R1175 monomethylation, another seven potential EGFR methylation sites were
identified in our mass spectrometry analysis, including one dimethylated lysine
(K704), three monomethylated lysines (K713, K946 and K1037), two
monomethylated arginines (R752 and R962) and one dimethylated arginine
(R1076).
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Figure 15. Summary of EGFR post-translational modifications
B. Schematic representation of the functional domains of EGFR intracellular
domain (amino acid 645-1186), including a juxtamembrane domain (JM, amino
acid 645-683), a tyrosine kinase domain (KD, amino acid 683-959) and a
C-terminal tail region (CT, amino acid 959-1186). The relative positions of known
EGFR post-translational modifications[10, 64], including phosphorylation (P),
ubiquitination (U), acetylation (A) and also the methylation (M) sites we identified
are indicated. Alphabets indicate the amino acid residues subjected to
modifications (T, threonine; S, serine; Y, tyrosine; K, lysine; R, arginine). Arabic
numbers indicate amino acid positions.
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Figure 16. MCF7-EGFR (Y1173F) cells exhibit lower cell growth and tumor
formation abilities than MCF7-EGFR (wt) cells
A. Western blot analysis of MCF7 stable transfectants expressing EGFR (wt),
EGFR (Y1173F), EGFR (R1175K) or empty vector.
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Figure 16. MCF7-EGFR (Y1173F) cells exhibit lower cell growth and tumor
formation abilities than MCF7-EGFR (wt) cells
B. In vitro cell proliferation assay of the stable transfectants using the MTT
colorimetric method. Error bars represent s.d. (n = 5).

C. In vivo cell proliferation of the stable transfectants in an orthotopic breast
cancer mouse model. Error bars represent s.d. (n = 10).
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Figure 17. Knockdown of endogenous SHP1 enhances EGF-stimulated SOS
phosphorylation and ERK activation
A. Western blot analysis of endogenous EGFR, ERK and AKT in EGF-stimulated
MDA-MB-468 cells transfected with control or SHP1 siRNA.
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Figure 17. Knockdown of endogenous SHP1 enhances EGF-stimulated SOS
phosphorylation and ERK activation
B. Western blot analysis of the tyrosine phosphorylation status of SOS, SHC and
Grb2 immunoprecipitated from EGF-stimulated MDA-MB-468 cells transfected
with control or SHP1 siRNA.
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Figure 17. Knockdown of endogenous SHP1 enhances EGF-stimulated SOS
phosphorylation and ERK activation
C. Western blot analysis of the tyrosine phosphorylation status of SOS, SHC and
Grb2 immunoprecipitated from EGF-stimulated MCF7-EGFR (wt), MCF7-EGFR
(Y1173F) and MCF7-EGFR (R1175K) stable transfectants.
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Figure 18. Expression of cytosolic Mep50 enhances R1175 methylation and
inhibits cell growth
A. Western blot analysis of EGFR and Mep50 in the MCF7-EGFR (wt) cells
ectopically expressed with NES (nuclear exporting signal)-fused Mep50, NLS
(nuclear localization signal)-fused Mep50, or empty vector.

B. In vitro cell proliferation assay of the MCF7-EGFR stable transfectants
expressed with NES-Mep50 or vector. Error bars represent s.d. (n = 5).

75

CHAPTER 9

FUTURE DIRECTIONS

9.1 Further elucidation of the functions of individual methylations or the
interrelationships between methylations and other modifications
In addition to R1175 methylation, several methylation sites are also identified
in current study, some of which are close to, or even overlap with, other known
modifications that play critical roles in the regulation of EGFR functionalities
(Figure 15). This suggests that protein methylation may have more in-depth
participation in the EGFR signaling and this field is worthwhile to be pursued
further to make the EGFR signalosome more comprehensive.

9.2 Identification of the regulatory mechanism and physiological relevance
of EGFR R1175 methylation
Our current study shows that EGFR R1175 methylation is involved in the
downstream ERK activation. However, it is still unclear clear what kind of
extracellular stimulus can lead to change of the EGFR methylation status and
which type of biological process is regulated by EGFR methylation. Our data imply
that EGFR R1175 methylation could be controlled by the cytoplasmic distribution
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of Mep50 (Figure 18) and may involve in the regulation of breast cancer cell
growth in different pathological stages. The role of EGFR methylation in breast
cancer progression will be further studied.
In addition, EGFR methylation might also involve in the proliferation and
differentiation of stem cells. In Drosophila models, EGFR-RAS-ERK and
JAK-STAT pathways are identified as two important participants in mediating
intestinal stem cell proliferation and differentiation and maintaining midgut
epithelial homeostasis in response to damage or stress[123, 124]. Later studies
indicate that these two signalings work cooperatively. JAK-STAT pathway-induced
stem cell proliferation is dependent on EGFR signaling[125], but the
exact mechanism is unclear. Recently, two separate studies reveal that
PRMT5-Mep50 complex suppresses embryonic stem cell differentiation[90] and
JAK2V617F, a constitutively active mutant of JAK2, promotes hematopoietic stem
cell proliferation and differentiation through phosphorylating PRMT5, disrupting
PRMT5-Mep50 association and inactivating PRMT5[96]. Moreover, our finding
show that PRMT5-mediated EGFR methylation is a negative modulator of
EGFR-RAS-ERK signaling. Taken all these results together, we predict that EGFR
methylation might be regulated by JAK2 phosphorylation-mediated PRMT5
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inactivation and involve in the regulation of stem cell proliferation and
differentiation (Figure 19).
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Figure 19. Potential connections between JAK2 signaling, EGFR signaling
and PRMT5-Mep50 complex in regulating stem cell proliferation and
differentiation.
The PRMT5-Mep50 complex methylates EGFR and inhibits EGFR-mediated ERK
activation. JAK2 kinase may activate the EGFR-ERK pathway through directly
phosphorylating EGFR, or disrupting the association between PRMT5 and
Mep50.
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